Dizal’s ZEGFROVY Outperforms Chemotherapy in NSCLC
SHANGHAI, China, May 29, 2026 Dizal has announced groundbreaking results from the global Phase 3 WU-KONG28 trial, demonstrating that...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SHANGHAI, China, May 29, 2026 Dizal has announced groundbreaking results from the global Phase 3 WU-KONG28 trial, demonstrating that...
BOSTON, Massachusetts, May 31, 2026 Servier has announced extended follow-up results from the pivotal Phase 3 INDIGO trial, demonstrating...
Paris, France – April 22, 2026 In a major breakthrough for pediatric oncology, Ipsen has announced that the European...
